33 results
Filters • 3
Sort By
Results Per Page
Filters
33 results
3
Download the following citations:
Email the following citations:
Print the following citations:
  • Mombelli M
  • Neofytos D
  • Huynh-Do U
  • Sánchez-Céspedes J
  • Stampf S
  • et al.
Clin Infect Dis. 2024 Jan 25;78(1):48-56 doi: 10.1093/cid/ciad477.
CET Conclusion
Reviewer: Mr John Fallon, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This large multi-centre double-blinded randomised trial demonstrated a higher vaccine response using MF59-adjuvanated and high-dose influenza vaccines compared with standard vaccine, but this did not lead to improved clinical outcomes, with no difference in the incidence of influenza. Overall, the trial is robustly designed with clear outcome measures, though choosing the main clinically relevant outcome, clinical efficacy, as a secondary measure due the samples size this would require. The vaccine response in standard vaccine was 42%, 60% in MF-59-adjuvanted and 66% in the high dose group, while these differences are significant, if it does not translate to clinical outcome it is more difficult to make a case for their use given the increased cost and potential side effect burden. Adverse events occurred in 84% and 86% in the MF59-adjuvanted and high dose cohorts and only 59% for the standard vaccine, but all were mild side effects, such as: pain, redness, swelling, arthralgia, fatigue, and headache. De novo anti-HLA antibodies and biopsy-proven acute rejection was rare across all groups. Despite the vaccine response rate differences, when scrutinising seroprotection by strains within the trivalent vaccine (H1N1, H3N2 & B), one can see the potential cause for the lack of clinical efficacy. Across all three groups baseline protection is around 60% for H1N1 and around 30% for the other strains, likely due to the large number of participants (83%) who have previously received an influenza vaccine, and given the majority of participants are primary recipients, they are likely to have been immunocompetent at the time of the previous vaccine. They have demonstrated MF59-adjuvanted and high-dose vaccines to be safe in the solid organ transplant population, and given pervious evidence of clinical benefit in high risk populations such as the elderly, these vaccine could provide clinical benefit in transplant populations, but definitive evidence to alter practice is not provided here.
Aims: They aimed to evaluate whether MF59-adjuvanated or high-dose influenza vaccines elicited better immunogenicity, were safe had better clinical efficacy compared to standard vaccine.
Interventions: Intervention vaccines were MF59-adjuvanated and high-dose influenza vaccine versus control, standard influenze vaccine.
Participants: 598 adults who received a solid organ transplant >3 months prior to enrolment.
Outcomes: The primary outcome was antibody response rate at day 2 post-vaccine. The secondary clinical outcomes were influenza confirmed on PCR and vaccine reactogenicity. The secondary immunogenicity outcomes were: geometric mean titres of haemagglutination inhibition, seroproctection rates, seroconversion rates, seroconversion factors for each strain.
Follow Up: 180 days
BACKGROUND:

The immunogenicity of the standard influenza vaccine is reduced in solid-organ transplant (SOT) recipients, so new vaccination strategies are needed in this population.

METHODS:

Adult SOT recipients from 9 transplant clinics in Switzerland and Spain were enrolled if they were >3 months after transplantation. Patients were randomized (1:1:1) to a MF59-adjuvanted or a high-dose vaccine (intervention), or a standard vaccine (control), with stratification by organ and time from transplant. The primary outcome was vaccine response rate, defined as a ≥4-fold increase of hemagglutination-inhibition titers to at least 1 vaccine strain at 28 days postvaccination. Secondary outcomes included polymerase chain reaction-confirmed influenza and vaccine reactogenicity.

RESULTS:

A total of 619 patients were randomized, 616 received the assigned vaccines, and 598 had serum available for analysis of the primary endpoint (standard, n = 198; MF59-adjuvanted, n = 205; high-dose, n = 195 patients). Vaccine response rates were 42% (84/198) in the standard vaccine group, 60% (122/205) in the MF59-adjuvanted vaccine group, and 66% (129/195) in the high-dose vaccine group (difference in intervention vaccines vs standard vaccine, 0.20; 97.5% confidence interval [CI], .12-1); P < .001; difference in high-dose vs standard vaccine, 0.24 [95% CI, .16-1]; P < .001; difference in MF59-adjuvanted vs standard vaccine, 0.17 [97.5% CI, .08-1]; P < .001). Influenza occurred in 6% of the standard, 5% in the MF59-adjuvanted, and 7% in the high-dose vaccine groups. Vaccine-related adverse events occurred more frequently in the intervention vaccine groups, but most of the events were mild.

CONCLUSIONS:

In SOT recipients, use of an MF59-adjuvanted or a high-dose influenza vaccine was safe and resulted in a higher vaccine response rate.

CLINICAL TRIALS REGISTRATION:

Clinicaltrials.gov NCT03699839.

  • Westphal GA
  • Robinson CC
  • Giordani NE
  • Teixeira C
  • Rohden AI
  • et al.
JAMA Netw Open. 2023 Dec 1;6(12):e2346901 doi: 10.1001/jamanetworkopen.2023.46901.
CET Conclusion
Reviewer: Mr Keno Mentor, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: Potential brain-dead organ donors are frequently lost to cardiac arrest prior to organ retrieval. This unblinded randomised trial investigated the efficacy of employing an ICU-based checklist to optimise donor physiology to reduce the rate of donor loss. The checklist included various aspects of critical care management and was randomised to 743 patients (vs. 792 controls). Although there was a numerical improvement in the intervention group, there was no significant difference in rate of donor loss between the two groups. There are several important confounders that are not controlled for in this trial, but the most important limitation is due to the lack of blinding. ICU units in the control arm could have improved their practice in response to being included in such a trial, negating any potential effect due to the intervention.
Aims: This study aimed to investigate the whether an evidence-based, goal-directed checklist was effective in delaying cardiac arrest in brain-dead potential donors in the intensive care unit (ICU).
Interventions: At cluster level, eligible hospitals were randomised to provide either checklist guidance or usual care. At individual level, potential organ donors were randomised to receive either checklist guidance or usual care.
Participants: At cluster level, hospitals with a mean number of ≥ 10 brain-dead potential donors annually over the previous 2 years were eligible. At individual level, brain dead organ donors in the ICU (aged 14 to 90 years) were enrolled.
Outcomes: The primary endpoint was the loss of brain-dead potential donors to cardiac arrest. The secondary endpoints included the conversion of brain-dead potential donors to actual organ donors and the number of solid organs recovered per actual organ donor.
Follow Up: 14 days or until transfer from the ICU to the operating room
IMPORTANCE:

The effectiveness of goal-directed care to reduce loss of brain-dead potential donors to cardiac arrest is unclear.

OBJECTIVE:

To evaluate the effectiveness of an evidence-based, goal-directed checklist in the clinical management of brain-dead potential donors in the intensive care unit (ICU).

DESIGN, SETTING, AND PARTICIPANTS:

The Donation Network to Optimize Organ Recovery Study (DONORS) was an open-label, parallel-group cluster randomized clinical trial in Brazil. Enrollment and follow-up were conducted from June 20, 2017, to November 30, 2019. Hospital ICUs that reported 10 or more brain deaths in the previous 2 years were included. Consecutive brain-dead potential donors in the ICU aged 14 to 90 years with a condition consistent with brain death after the first clinical examination were enrolled. Participants were randomized to either the intervention group or the control group. The intention-to-treat data analysis was conducted from June 15 to August 30, 2020.

INTERVENTIONS:

Hospital staff in the intervention group were instructed to administer to brain-dead potential donors in the intervention group an evidence-based checklist with 13 clinical goals and 14 corresponding actions to guide care, every 6 hours, from study enrollment to organ retrieval. The control group provided or received usual care.

MAIN OUTCOMES AND MEASURES:

The primary outcome was loss of brain-dead potential donors to cardiac arrest at the individual level. A prespecified sensitivity analysis assessed the effect of adherence to the checklist in the intervention group.

RESULTS:

Among the 1771 brain-dead potential donors screened in 63 hospitals, 1535 were included. These patients included 673 males (59.2%) and had a median (IQR) age of 51 (36.3-62.0) years. The main cause of brain injury was stroke (877 [57.1%]), followed by trauma (485 [31.6%]). Of the 63 hospitals, 31 (49.2%) were assigned to the intervention group (743 [48.4%] brain-dead potential donors) and 32 (50.8%) to the control group (792 [51.6%] brain-dead potential donors). Seventy potential donors (9.4%) at intervention hospitals and 117 (14.8%) at control hospitals met the primary outcome (risk ratio [RR], 0.70; 95% CI, 0.46-1.08; P = .11). The primary outcome rate was lower in those with adherence higher than 79.0% than in the control group (5.3% vs 14.8%; RR, 0.41; 95% CI, 0.22-0.78; P = .006).

CONCLUSIONS AND RELEVANCE:

This cluster randomized clinical trial was inconclusive in determining whether the overall use of an evidence-based, goal-directed checklist reduced brain-dead potential donor loss to cardiac arrest. The findings suggest that use of such a checklist has limited effectiveness without adherence to the actions recommended in this checklist.

TRIAL REGISTRATION:

ClinicalTrials.gov Identifier: NCT03179020.

  • Karar H
  • Shafiekhani M
  • Mahmoudi MM
  • Azadeh N
  • Shamsaeefar A
  • et al.
BMC Res Notes. 2023 Oct 26;16(1):295 doi: 10.1186/s13104-023-06568-9.
CET Conclusion
Reviewer: Mr Keno Mentor, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This non-blinded randomised study compared two techniques for arterial anastomosis of the pancreas graft in simultaneous pancreas/kidney (SPK) transplant. The standard technique involves using a ‘y-graft’ derived from the bifurcation of the common iliac into the internal and external iliac arteries, while the modified technique tested in this study uses this standard technique with the addition of an extension graft derived from donor carotid artery. 30 patients were randomised equally between the two groups with no significant differences found in the primary outcomes of post-operative thrombosis, pancreatitis and surgical site infection. Small patient numbers and a lack of analysis of important donor and graft confounding factors (e.g. donor age, cold ischaemic time, etc) mean these findings cannot be generalised.
Aims: The aim of this study was to examine whether a novel technique for arterial reconstruction improves post-surgical outcomes in SPK transplant receipts.
Interventions: Participants were randomised to receive either the the Y-graft technique or the Y-graft and extension technique.
Participants: 30 simultaneous pancreas-kidney transplant recipeints.
Outcomes: The main clinical outcomes of this study were incidence of the post-surgical complications (pancreatitis, vascular events, fistula formation, and rejection).
Follow Up: 3 months following transplantation
INTRODUCTION:

Simultaneous pancreas kidney (SPK) transplantation is an invaluable procedure to enhance the quality of life of insulin-dependent patients with advanced renal disease. The creation of vascular anastomoses of the donor's pancreas vessels to the recipient's, is of utmost importance to predict the graft outcome and surgical complications. In the study we introduce a novel technique for arterial reconstruction during SPK transplantation.

METHODS:

Conventionally, during the SPK transplantation, a so-called Y-graft is anastomosed between donor's superior mesenteric and splenic artery to the recipient's right iliac artery. In the study we adopted a new technique by preparing an extra extension using the donor's carotid artery, to be anastomosed to the Y-graft and the iliac artery. In this non-blinded randomized clinical trial we compared the surgical complications and early outcomes between the 2 groups of patients with the traditional and new arterial reconstruction techniques during 3 months after transplantation.

RESULTS:

Thirty adult patients were included in the study. The incidence of pancreatitis, vascular thrombosis and surgical site infection was lower in the new Y-graft and extension technique, which was not statistically significant. However, the calculated Cohen's d index showed the medium effect of new Y-graft and extension technique on complication after SPK transplantations.

CONCLUSION:

The post-operative complications tend to be lower in the novel arterial reconstruction technique, however a study on a larger patient group is encouraged to confirm our primary results.

TRIAL REGISTRATION:

The study was registered at the Iranian Registry of Clinical Trials on 12/05/2022; IRCT 20210625051701N2; ( http://www.irct.ir/ ).

  • Pekmezaris R
  • Cigaran E
  • Patel V
  • Clement D
  • Sardo Molmenti CL
  • et al.
World J Transplant. 2023 Jun 18;13(4):190-200 doi: 10.5500/wjt.v13.i4.190.
CET Conclusion
Reviewer: Mr Simon Knight, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This randomised study from New York recruited adult Hispanic residents and delivered an online survey to elicit their knowledge and views on organ donation. Participants were randomised to watch an emotive video on deceased donation either before answering the survey, or after. The authors found that participants who watched the video before answering the survey showed more willingness to register as a donor (OR 2.05) and greater awareness as to how to sign up. The study is well designed and interesting, demonstrating how simple information provision may impact donation decisions in diverse populations. It is worth noting that the study did not measure actual registrations, just intent, and future studies should look at impact on actual registration rates as a closer proxy to real-world benefit.
Aims: The aim of this study was to evaluate whether an educational video was effective in improving organ donation intent among Hispanic New York residents.
Interventions: Participants were randomised to either view a short educational video on organ donation prior to the survey or to view the same video following the survey.
Participants: 365 Hispanic New York City (NYC) residents.
Outcomes: The main outcomes of interest were to assess the impact of the emotional video on willingness to donate, and to identify driving factors for organ donation.
Follow Up: N/A
BACKGROUND:

The Hispanic community has a high demand for organ donation but a shortage of donors. Studies investigating factors that could promote or hinder organ donation have examined emotional video interventions. Factors acting as barriers to organ donation registration have been classified as: (1) Bodily integrity; (2) medical mistrust; (3) "ick"-feelings of disgust towards organ donation; and (4) "jinx"-fear that registration may result in one dying due to premeditated plans. We predict that by providing necessary information and education about the donation process via a short video, individuals will be more willing to register as organ donors.

AIM:

To determine perceptions and attitudes regarding barriers and facilitators to organ donation intention among Hispanic residents in the New York metro politan area.

METHODS:

This study was approved by the Institutional Review Board at Northwell Health. The approval reference number is No. 19-0009 (as presented in Supplementary material). Eligible participants included Hispanic New York City (NYC) residents, 18 years of age and above, who were recruited voluntarily through Cloud Research and participated in a larger randomized survey study of NYC residents. The survey an 85-item Redcap survey measured participant demographics, attitudes, and knowledge of organ donation as well as the intention to register as an organ donor. Attention checks were implemented throughout the survey, and responses were excluded for those who did fail. Participants were randomly assigned two-between subject conditions: To view a short video on organ donation and then proceed to complete the survey (i.e., video first) and view the same video at the end of the survey (video last). No intra-group activities were conducted. This study utilized an evidenced-based emotive educational intervention (video) which was previously utilized and was shown to increase organ donation registration rates at the Ohio Department of Motor Vehicles. Results were analyzed using Jamovi statistical software. Three hundred sixty-five Hispanic individuals were included in the analysis. Once consent was obtained and participants entered the survey (the survey sample is presented in Supplementary material), participants were asked to report on demographic variables and their general impression of organ donation after death. The video depicted stories regarding organ donation after death from various viewpoints, including from the loved ones of a deceased person who died waiting for a transplant; from the loved ones of a deceased person whose organs were donated upon death; and, from those who were currently waiting for a transplant.

RESULTS:

Using a binomial logistic regression, the analysis provides information about the relationship between the effects of an emotive video and the intention to donate among Hispanic participants who were not already registered as donors. The willingness to go back and register was found to be significantly more probable for those who watched the emotive video before being asked about their organ donation opinions (odds ratio: 2.05, 95% confidence interval: 1.06-3.97). Motivations for participation in organ donation were also captured with many stating the importance of messages coming from "people like me" and a message that highlights "the welfare of those in need". Overall, the findings suggest that using an emotive video that addresses organ donation barriers to prompt organ donation intentions can be effective among the Hispanic populous. Future studies should explore using targeted messaging that resonates with specific cultural groups, highlighting the welfare of others.

CONCLUSION:

This study suggests that an emotive educational intervention is likely to be effective in improving organ donation registration intent among the Hispanic population residing in NYC.

  • Zhang W
  • Feng X
  • Deng X
  • Jin M
  • Li J
  • et al.
Gland Surg. 2023 May 30;12(5):619-627 doi: 10.21037/gs-23-116.
CET Conclusion
Reviewer: Mr John O'Callaghan, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This paper reports on a relatively large randomised controlled trial in kidney-pancreas transplantation. The key criticism of this paper is a lack of detail about what the control level of care was. The nurse-led MDT that was introduced is described in detail as a well-organised, responsive and well staffed system. It is not clear if this was compared to a control system of care that was completely unstructured and therefore unsurprising that there was a difference in patient outcomes. It is not clear if only a nurse-led MDT is required, or if the same result would have been seen with the introduction of such a well-structured scheme with a different lead clinician. The study included 218 patients and the intervention group had a significantly shorter length of stay, higher patient satisfaction, lower readmission rate, and pulmonary infection. The method of randomisation is not described and the study was only blinded for data analysis. The study was powered to detect a reduction in gastrointestinal (GI) bleeding, which seems like a very unusual primary outcome for such a study.
Aims: The aim of this study was to investigate the application of a transplant nurse-led multidisciplinary team (MDT) in the perioperative care of simultaneous pancreas and kidney transplantation (SPKT) patients.
Interventions: Participants were randomised to receive either the nurse-led MDT intervention group or the conventional care group.
Participants: 218 SPKT recipients.
Outcomes: The main outcomes of interest were incidence of postoperative complications, hospital stay, readmission rate, total cost of hospitalization and quality of postoperative nursing.
Follow Up: N/A
BACKGROUND:

Simultaneous pancreas and kidney transplantation (SPKT) is an effective treatment option for individuals who suffer from both diabetes mellitus and renal failure. However, experiments exploring nurse-led multidisciplinary team management during the perioperative management of patients undergoing SPKT are currently limited. This study aims to explore the clinical performance of a transplant nurse-led multidisciplinary team (MDT) in the perioperative management of SPKT patients.

METHODS:

A total of 218 patients who underwent SPKT were randomly assigned to either a control group (n=116) receiving conventional care or an intervention group (n=102) managed through a transplant nurse-led MDT approach. The incidence of postoperative complications, hospital stay, total hospitalization cost, readmission rate, and postoperative nursing quality were compared between these 2 groups.

RESULTS:

The intervention and control groups showed no significant differences in age, gender, and body mass index. Compared with the control group, the intervention group had a significantly lower incidence of postoperative pulmonary infection and gastrointestinal (GI) bleeding (27.6% vs. 14.7% and 31.0% vs. 15.7%, respectively, both P<0.05). Compared to the control group, the intervention group had significantly lower hospitalization costs, length of hospital stay, and readmission rate 30 days after discharge (32.98±9.10 vs. 36.78±15.36, 26.47±13.4 vs. 31.03±11.61 and 31.4% vs. 50.0%, respectively, all P<0.05). Additionally, the intervention group had significantly better quality of postoperative nursing care than the control group (11.61±0.69 vs. 9.64±1.42, P<0.01), the availability of infection control and prevention measures (11.74±0.61 vs. 10.53±1.11, P<0.01), the effectiveness of health education (11.73±0.61 vs. 10.41±1.06, P<0.01), the effectiveness of rehabilitation training (11.77±0.54 vs. 10.37±0.96, P<0.01), and the patient satisfaction with nursing care (11.83±0.42 vs. 10.81±1.08, P<0.01).

CONCLUSIONS:

The nurse-led MDT model for transplant patients can reduce complications, shorten hospital stays, and save costs. It also provides clear guidelines for nurses, improving care quality and aiding patient recovery.

TRIAL REGISTRATION:

Chinese Clinical Trial Registry ChiCTR1900026543.

  • Tang J
  • He R
  • Zhang L
  • Xu S
Ann Transplant. 2023 May 23;28:e940211 doi: 10.12659/AOT.940211.
CET Conclusion
Reviewer: Mr John O'Callaghan, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This is a small randomised controlled trial in anaesthesia for simultaneous kidney-pancreas transplantation. Reversal of neuromuscular blockade with sugammadex is compared to neostigmine. There is great detail in the methods regarding the anaesthetic procedures and processes but there is no description of the randomisation or blinding. The study was powered for a significant improvement in the number of patients reaching TOFratio >0.9 within 40 minutes (essentially the reversal of neuromuscular blockade). There was a significantly faster reversal of neuromuscular blockade with sugammadex administration than neostigmine (median 3 minutes versus median 12 minutes). Time to extubation and length of PACU stay were also significantly reduced. There were no safety concerns in terms of renal function or other complications, but only 7 days follow up is reported.
Aims: The aim of this study was to determine the effect of sugammadex in simultanous pancreas-kidney (SPK) transplant recipients.
Interventions: Participants were randomised to receive either a sugammadex injection or the neostigmine-atropine complex.
Participants: 50 SPK transplant recipients.
Outcomes: The main outcomes of interest included assessment of blood glucose, serum creatinine, creatinine clearance rate, mean arterial pressure, serum amylase, heart rate, time from sugammadex/neostigmine administration at the scheduled time to recovery, and post-acute pulmonary complications.
Follow Up: 108 hours following surgery

BACKGROUND Simultaneous pancreas-kidney transplantation (SPK) is a time-consuming and important surgical procedure, which can provide a physiological mean of achieving normoglycemia and render patients free of dialysis. The potential clinical benefits of sugammadex include fast and predictable reverse deep neuromuscular blockade (NMB), but whether sugammadex affects the function of SPK grafts is uncertain. MATERIAL AND METHODS Forty-eight patients were studied and reversed deep NMB with either sugammadex (n=24) or neostigmine (n=24). The safety variables included serum creatinine (Scr), creatinine clearance rate (CCr), serum amylase (AMS), blood glucose (Glu), mean arterial pressure (MAP), and heart rate (HR). Secondary outcomes were time from administration of sugammadex/neostigmine at the scheduled time to recovery of a TOF ratio to 0.7 and 0.9, and post-acute pulmonary complications. RESULTS Scr at T2-6 was significantly lower than that at T0-1 (P<0.01), while CCr was higher (P<0.05). Between the 2 groups, Scr, CCr, and AMS were similar at the same timepoints (P>0.05). MAP, HR, and Glu were higher in group S than in group N at T1 (P<0.05). The recovery time of TOF=0.7 was 3 (2.4-4.2) min for group S and 12.1 (10.2-15.9) min for group N (P<0.001), and recovery time to TOFr ≥0.9 was 4.8 (3.6-7.1) min for group S and 23.5 (19.8-30.8) in group S. Compared to group N, group S had lower risk for post-acute pulmonary complications: supplemental oxygen requirements 0 vs 4 (16.7%), pulmonary atelectasis 0 vs 2 (0.83%), pneumonia 1 (4.2%) vs 3 (12.5%), and hypoxemia 1 (4.2%) vs 4 (16.7%). CONCLUSIONS Sugammadex administration is safe and effective for SPK transplantation recipients.

  • Shepherd L
  • O'Carroll RE
  • Ferguson E
Soc Sci Med. 2023 Jan;317:115545 doi: 10.1016/j.socscimed.2022.115545.
CET Conclusion
Reviewer: Reshma Rana Magar, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This study aimed to establish whether factors such as anticipated regret, the deceased wishes and next-of-kin attitudes could predict next-of-kin approval for organ donation, and to develop a model of next-of-kin decision making regarding organ donation in Wales, UK, which has an opt-out system. A total of 808 participants were randomly assigned to imagine whether a deceased relative had either opted-in, opted-out or had not registered a decision (deemed consent). The authors concluded that anticipated regret significantly influenced the next-of-kin approval for organ donation, and also that if the next-of kin had negative beliefs towards organ donation, they were less likely to follow the deceased wishes to donate. It is possible that the participants may have underestimated the influence of their emotions on future decision-making process; thus, how they believed they would act may be different from how they behave in real life. The authors do a good job of acknowledging this. However, the study did not assess ethnicity or religion, both of which have been found to affect the decision of the next-of-kin on organ donation. These could have acted as potential confounders in the analyses. Perhaps another factor the authors could have also considered is the type of relationship between the deceased donor and the next-of-kin. It would have been interesting to see if relatives with negative attitude towards organ donation were able to override their beliefs and follow the deceased donor’s wishes to donate if the deceased donor was an authority figure or a final decision maker when alive. For example, in cultures where fathers are the main decision makers, there may be a higher chance of sons/daughters respecting their deceased father’s wishes to donate despite their negative affective attitudes, in comparison to fathers respecting their deceased children’s wishes.
Aims: This study aimed to investigate how the deceased donor’s wishes, negative affective attitudes, perceived benefits and anticipated regret had an effect on the next-of-kin’s approval of organ donation under opt-out legislation.
Interventions: Participants were randomised to imagine if their deceased relative had either opted in, opted-out or not registered a decision (deemed consent).
Participants: Adults (≥18 years) living in Wales.
Outcomes: The outcome variables of interest included previous health-based philanthropy, uncertainty, anticipated regret, intention of next-of-kin to approve donation of organs, negative affective attitudes and perceived benefits.
Follow Up: Not reported
RATIONALE:

Family, and sometimes longstanding friends, have considerable influence over organ donation, through agreeing or disagreeing to the donation of a deceased individual's organs. To date, most research has been undertaken within opt-in systems.

OBJECTIVE:

This study advances on previous research by assessing next-of-kin approval under opt-out legislation. We tested whether next-of-kin approval varies when the deceased is a registered donor (opted-in), registered non-donor (opted-out) or has not registered a decision under an opt-out policy (deemed consent). We also tested if the deceased's wishes influenced next-of-kin approval through relatives anticipating regret for not donating and feelings of uncertainty. Finally, we assessed whether next-of-kin's own beliefs about organ donation influenced whether they followed the deceased's wishes.

METHODS:

Participants (N = 848) living in a country with opt-out legislation (Wales, UK) were asked to imagine a relative had died under an opt-out system and decided if their relatives' organs should be donated. Participants were randomly allocated to imagine the deceased had either (i) opted-in, (ii) opted-out or (iii) not registered a decision (deemed consent). The outcome variable was next-of-kin approval, with uncertainty and anticipated regret as potential mediators and next-of-kin's beliefs about organ donation as moderators.

RESULTS:

Next-of-kin approval was lower when the deceased had opted-out than under deemed consent. This was due to next-of-kin anticipating more regret for not donating under deemed consent than opt-out. Further analyses revealed the deceased's wishes influence next-of-kin approval, via anticipated regret, when next-of-kin did not hold negative beliefs about organ donation.

CONCLUSIONS:

The deceased's wishes were less likely to be followed when next-of-kin had negative beliefs towards donation. Developing large-scale campaigns to improve these beliefs in the general public should make people more likely to follow the deceased's wishes. As a result, these campaigns should improve the availability of donor organs.

  • Dong A
  • Zhang Y
  • Lu S
  • Yu W
Evid Based Complement Alternat Med. 2022 Nov 17;2022:7196449 doi: 10.1155/2022/7196449.
CET Conclusion
Reviewer: Mr John O'Callaghan, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences
Conclusion: In this RCT, patients undergoing simultaneous kidney pancreas transplant were randomised to receive an infusion of dexmedetomidine or saline. Patients were blinded to their group allocation. There were no significant differences in haemodynamic measures intra-operatively. TNF-alpha and IL-6 in the serum was significantly higher in the control group than the study group from 30 minutes into surgery until 24 hours after. Immediately after surgery cardiac troponin was significantly higher in the control group than the study group. The rise in CK-MB in both groups also fell away quicker in the study group after surgery. There was no statistically significant difference in intra-operative cardiac events or ECG changes. The study shows an ischaemia- reperfusion event after pancreas and kidney reperfusion, with possible cardiac effects. There is no power calculation and it is not clear what the primary outcome was, so the study may be underpowered.
Aims: This study aimed to investigate the effect of dexmedetomidine (Dex) on myocardial injury in simultaneous pancreas-kidney transplant recipients.
Interventions: Participants were randomised to either the dexmedetomidine (Dex) group or the saline (control) group.
Participants: 94 simultaneous pancreas-kidney transplant recipients.
Outcomes: The outcomes of interest were changes in group haemodynamic variables, differences in inflammatory factors and myocardial injury biomarkers between the Dex and the control group, and intraoperative adverse cardiovascular events.
Follow Up: 1 year
BACKGROUND:

Diabetes is one of the most common chronic diseases in the world. End-stage renal disease (ESRD) caused by diabetes is the most serious long-term complication. The main cause of death in patients with simultaneous pancreas-kidney transplantation (SPKT) is cardiovascular disease. Although dexmedetomidine (Dex) has unique advantages in heart protection against ischaemic/reperfusion injury, few clinical studies have been conducted on its cardioprotective effect in SPKT. This study aimed to explore the influence of Dex on myocardial injury in patients undergoing SPKT and to analyze its possible mechanism.

METHODS:

A randomized controlled trial (RCT) was performed from July 1, 2018 to December 1, 2020. Eighty patients, regardless of gender, scheduled for SPKT were randomly allocated into a Dex group (D group) receiving Dex at a rate of 1 µg/kg for 10 minutes before anaesthesia induction and then continuous infusion at 0.5 µg/kg/hour until the end of surgery and control group (C group) receiving equivalent capacity of saline. Serum cardiac troponin I (cTnI), creatine kinase isoenzyme (CK-MB), tumour necrosis factor-α (TNF-α), and interleukin-6 (IL-6) were recorded at 5 minutes after anaesthesia induction (baseline,T0), 5 minutes before renal arteriovenous opening (T1), 30 minutes after renal arteriovenous opening (T2), 30 minutes after pancreatic related arteriovenous opening (T3), immediately after surgery (T4), 4 hours after surgery (T5), and 24 hours after surgery (T6). Adverse cardiovascular events were recorded during the perioperative period. Changes in ECG S-T segments and T waves were monitored at T0-T6. Myocardial infarction and percutaneous coronary intervention were recorded with an average follow-up of one year.

RESULTS:

Compared with T0, TNF-α and IL-6 concentrations significantly increased at T1-T6 in the C and D groups (P < 0.05). IL-6 concentration increased significantly after renal artery opening and reached the peak after the opening of pancreatic blood vessels. Compared with the C group, TNF-α, and IL-6 concentrations were significantly reduced in group D at T2-T6 (P < 0.05). Compared with T0, cTnI and CK-MB concentrations were significantly increased at T3-T6 in the C and D groups (P < 0.05). cTnI and CK-MB concentrations increased significantly after the opening of renal artery, and reached the peak after the opening of pancreatic blood vessels. Compared with the C group, cTnI and CK-MB concentrations were significantly reduced in the D group at T3-T6 (P < 0.05). There was no significant difference in patient characteristics amongst groups, including the proportion of intraoperative vasoactive drug use and adverse cardiovascular events during the follow-up period. Heart rate, mean blood pressure, central venous pressure, and cardiac output were not remarkably different between the two groups at any time point.

CONCLUSIONS:

Perioperative reperfusion could aggravate myocardial injury in SPKT. Dex may be considered a way to reduce myocardial injury caused by inflammatory action by decreasing the release of inflammatory factors. Trial Registration Number: Chinese Clinical Trial Registry ID: ChiCTR2200060084.

  • Avery RK
  • Alain S
  • Alexander BD
  • Blumberg EA
  • Chemaly RF
  • et al.
Clin Infect Dis. 2022 Sep 10;75(4):690-701 doi: 10.1093/cid/ciab988.
CET Conclusion
Reviewer: Mr Simon Knight, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This multicentre RCT investigated the use of Maribavir (a UL97 protein kinase inhibitor) in post-transplant (HCT or SOT) patients with refractory CMV infection. Maribavir was compared to investigator assigned treatment with either valganciclovir/ganciclovir, foscarnet, or cidofovir. CMV clearance was significantly more likely in the Maribavir group (55.7% vs 23.9%) and demonstrated less nephrotoxicity than foscarnet, and less myelosuppression than valganciclovir/ganciclovir. Whilst unblinded, the study is pragmatic and well designed. There is some variability in included patients (“refractory” patients had to have failed to respond to one first line therapy, but this was not specified in detail) and in the investigator assigned comparator group, but this likely reflects real-world variations in practice. The results encouraging for the use of Maribavir as an alternative, potentially less toxic, alternative to existing therapies in this setting.
Expert Review
Reviewer: Mr Simon Knight, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Clinical Impact Rating 4
Review: Treatment of refractory cytomegalovirus (CMV) infection in solid organ transplant recipients is challenging, with existing therapies limited by toxicity and drug resistance. Ganciclovir resistance is frequently seen, and foscarnet is associated with renal dysfunction in around 50% of patients treated (1). Safer, more effective treatments are needed to improve outcomes. Avery and colleagues have recently reported the outcomes of a multicentre, phase 3 randomised controlled trial of Maribavir, a novel UL97 protein kinase inhibitor that interferes with CMV DNA replication and encapsidation (2). The study randomised solid organ or stem cell transplant recipients with refractory CMV infection to Maribavir or investigator assigned treatment (IAT; valganciclovir/ganciclovir, foscarnet or cidofovir). Maribavir-treated patients demonstrated significantly higher clearance of viraemia after 8 weeks of treatment compared to IAT (55.7% vs. 23.9%). This response also appeared more sustained with Maribavir, with more patients achieving viraemia clearance and symptom control through to week 16. Perhaps as importantly, Maribavir also appeared to have an improved safety profile compared to other agents. Incidence of renal dysfunction was lower than with foscarnet, and neutropenia was less frequent than valganciclovir/ganciclovir. Dysguesia was the most frequently reported side effect in Maribavir-treated patients. Overall, fewer patients discontinued therapy due to side effects than in the IAT group. The study is pragmatic and well designed. It is not blinded, although this would be challenging give n the different routes of administration of the various agents. There is some variability in included patients (“refractory” patients had to have failed to respond to one first line therapy, but this was not specified in detail) and in the investigator assigned comparator group, but this likely reflects real-world variations in practice. Overall, the results are very encouraging and suggest that Maribavir offers an effective, better tolerated alternative to existing therapies for refractory CMV. References 1. Avery RK, Arav-Boger R, Marr KA et al. Outcomes in Transplant Recipients Treated With Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection. Transplantation 2016; 100: e74. 2. Avery RK, Alain S, Alexander BD et al. Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results from a Phase 3 Randomized Clinical Trial. Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America 2021; : ciab988.
Aims: This study aimed to investigate the safety and efficacy of maribavir compared to investigator-assigned therapy (IAT) for the treatment of with or without resistance cytomegalovirus (R/R CMV) infection in solid-organ transplant (SOT) and hematopoietic-cell transplant (HCT) recipients.
Interventions: Participants were randomised to either the maribavir group or the IAT group.
Participants: 352 HCT and SOT recipients.
Outcomes: The primary outcome was confirmed CMV viremia clearance. Secondary outcomes included achievement of CMV clearance and symptom control.
Follow Up: 16 weeks
BACKGROUND:

Therapies for refractory cytomegalovirus infections (with or without resistance [R/R]) in transplant recipients are limited by toxicities. Maribavir has multimodal anti-cytomegalovirus activity through the inhibition of UL97 protein kinase.

METHODS:

In this phase 3, open-label study, hematopoietic-cell and solid-organ transplant recipients with R/R cytomegalovirus were randomized 2:1 to maribavir 400 mg twice daily or investigator-assigned therapy (IAT; valganciclovir/ganciclovir, foscarnet, or cidofovir) for 8 weeks, with 12 weeks of follow-up. The primary endpoint was confirmed cytomegalovirus clearance at end of week 8. The key secondary endpoint was achievement of cytomegalovirus clearance and symptom control at end of week 8, maintained through week 16.

RESULTS:

352 patients were randomized (235 maribavir; 117 IAT). Significantly more patients in the maribavir versus IAT group achieved the primary endpoint (55.7% vs 23.9%; adjusted difference [95% confidence interval (CI)]: 32.8% [22.80-42.74]; P < .001) and key secondary endpoint (18.7% vs 10.3%; adjusted difference [95% CI]: 9.5% [2.02-16.88]; P = .01). Rates of treatment-emergent adverse events (TEAEs) were similar between groups (maribavir, 97.4%; IAT, 91.4%). Maribavir was associated with less acute kidney injury versus foscarnet (8.5% vs 21.3%) and neutropenia versus valganciclovir/ganciclovir (9.4% vs 33.9%). Fewer patients discontinued treatment due to TEAEs with maribavir (13.2%) than IAT (31.9%). One patient per group had fatal treatment-related TEAEs.

CONCLUSIONS:

Maribavir was superior to IAT for cytomegalovirus viremia clearance and viremia clearance plus symptom control maintained post-therapy in transplant recipients with R/R cytomegalovirus. Maribavir had fewer treatment discontinuations due to TEAEs than IAT. Clinical Trials Registration. NCT02931539 (SOLSTICE).

  • Aida N
  • Ito T
  • Kurihara K
  • Hiratsuka I
  • Shibata M
  • et al.
J Clin Med. 2022 Apr 18;11(8) doi: 10.3390/jcm11082258.
CET Conclusion
Reviewer: Mr Simon Knight, Centre for Evidence in Transplantation, Nuffield Department of Surgical Sciences University of Oxford
Conclusion: This small single-centre study from Japan investigates the role of common hepatic artery reconstruction in pancreas transplantation. 29 pancreas transplant recipients were randomised to reconstruction of the common hepatic artery or not. No differences in graft or patient survival, complication rate or graft function were seen between groups. Despite a sample size calculation performed on a non-inferiority basis, in reality the study is underpowered to show any difference between groups. The authors set a lower limit of non-inferiority in graft survival at 80%, which is a large difference from the baseline of 93.2% in their historic cohort. Randomisation was undertaken in blocks of two, meaning that there was no allocation concealment. Due to differences in national organ retrieval protocols, it is unlikely that reconstruction in this way would be possible in a lot of settings. In most regions, the splenic artery and SMA are reconstructed with a y-graft to allow the coeliac axis to be kept with the liver. This study suggests that reperfusion of the GDA is not usually required to provide adequate blood supply to the head of the pancreas.
Aims: This study aimed to assess the efficacy and effects of common hepatic artery (CHA) reconstruction in pancreas transplantation.
Interventions: Participants were randomised to either the non-reconstructed group or the reconstructed group.
Participants: 25 patients who underwent pancreas transplantation.
Outcomes: The primary outcomes were 1-year graft survival. The secondary outcomes were the incidence of perioperative complications, 1-year graft survival, 1-month and 1-year patient survival, graft endocrine function, and tissue perfusion.
Follow Up: 1 year

Maintenance of postoperative graft flow is important in pancreas transplantation. In Japan, reconstruction of the common hepatic artery is performed primarily to increase perfusion in the pancreatic head. We investigated the effects of common hepatic artery reconstruction on patient and graft survival and endocrine functions. Twenty-nine cases of pancreas transplantation were registered in the clinical trial. Of the 29 cases, four were excluded because of the risk of ischemia without reconstruction or complicated reconstruction due to a narrow artery. A total of 25 cases were randomized into two groups: 13 in the non-reconstructed group and 12 in the reconstructed group. The 1-year patient survival and graft survival rates of the non-reconstructed and reconstructed groups were 92.3% and 83.3%, and 91.7% and 82.5%, respectively. The incidence of complications in the two groups was comparable, with 38.5% (5/13 cases) in the non-reconstructed group and 33.3% (4/12 cases) in the reconstructed group. The results of the glucagon stimulation test and oral glucose tolerance test at 1 month and 1 year post-transplantation were comparable. Common hepatic artery reconstruction is not essential unless there is risk of ischemia. This study was registered at the University Hospital Medical Information Network Clinical Trials Registry under UMIN000027213.